Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1876 AL 1890

Amphetamine-induced rotation in the transplanted hemi-parkinsonian rat--response to pharmacological modulation

Smith GA, Dunnett SB, Lane EL.

Behav Brain Res. 2012 Jul 1;232(2):411-5. doi: 10.1016/j.bbr.2012.04.003. Epub 2012 Apr 9.

Factors contributing to spousal and offspring caregiver burden in Parkinson's disease

Shin H, Lee JY, Youn J, Kim JS, Cho JW.

Eur Neurol. 2012;67(5):292-6. doi: 10.1159/000335577. Epub 2012 Apr 17.

A Parkinson's disease patient with camptocormia caused by an esophageal hiatal hernia

Jang W, Kwon HS, Kim JS, Cho JH, Kim HT.

Mov Disord. 2012 Jun;27(7):922-3. doi: 10.1002/mds.24989. Epub 2012 Apr 19.

Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders

Salcedo I, Tweedie D, Li Y, Greig NH.

Br J Pharmacol. 2012 Jul;166(5):1586-99. doi: 10.1111/j.1476-5381.2012.01971.x.

Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson's disease

Santos-García D, Prieto-Formoso M, de la Fuente-Fernández R.

J Neurol Sci. 2012 Jul 15;318(1-2):90-3. doi: 10.1016/j.jns.2012.03.018. Epub 2012 Apr 21.

New insights on endocannabinoid transmission in psychomotor disorders

Giuffrida A, Seillier A.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):51-8. doi: 10.1016/j.pnpbp.2012.04.002. Epub 2012 Apr 10.

The immunological challenges of cell transplantation for the treatment of Parkinson's disease

Piquet AL, Venkiteswaran K, Marupudi NI, Berk M, Subramanian T.

Brain Res Bull. 2012 Jul 1;88(4):320-31. doi: 10.1016/j.brainresbull.2012.03.001. Epub 2012 Apr 11.

Paraoxonase 1 polymorphisms L55M and Q192R were not risk factors for Parkinson's disease: a HuGE review and meta-analysis

Liu YL, Yang J, Zheng J, Liu DW, Liu T, Wang JM, Wang CN, Wang MW, Tian QB.

Gene. 2012 Jun 15;501(2):188-92. doi: 10.1016/j.gene.2012.03.067. Epub 2012 Apr 9.

Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study

Utsumi H; Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group.

Acta Med Okayama. 2012;66(2):163-70. doi: 10.18926/AMO/48266.

Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest

Bartus RT.

Neurobiol Dis. 2012 Nov;48(2):153-78. doi: 10.1016/j.nbd.2012.04.004. Epub 2012 Apr 16.

A short scale for evaluation of neuropsychiatric disorders in Parkinson's disease: first psychometric approach

Martinez-Martin P, Frades-Payo B, Agüera-Ortiz L, Ayuga-Martinez A.

J Neurol. 2012 Nov;259(11):2299-308. doi: 10.1007/s00415-012-6490-x. Epub 2012 Apr 18.

Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients

Ferrari M, Martignoni E, Blandini F, Riboldazzi G, Bono G, Marino F, Cosentino M.

Eur J Clin Pharmacol. 2012 Nov;68(11):1493-9. doi: 10.1007/s00228-012-1281-y. Epub 2012 Apr 15.

Parkinsonism secondary to subdural haematoma

Gelabert-Gonzalez M, Serramito-García R, Aran-Echabe E.

Neurosurg Rev. 2012 Jul;35(3):457-60; discussion 460-1. doi: 10.1007/s10143-012-0386-1. Epub 2012 Apr 21.

Regulation of Parkin E3 ubiquitin ligase activity

Walden H, Martinez-Torres RJ.

Cell Mol Life Sci. 2012 Sep;69(18):3053-67. doi: 10.1007/s00018-012-0978-5. Epub 2012 Apr 19.

γ-Glutamyltranspeptidases: sequence, structure, biochemical properties, and biotechnological applications

Castellano I, Merlino A.

Cell Mol Life Sci. 2012 Oct;69(20):3381-94. doi: 10.1007/s00018-012-0988-3. Epub 2012 Apr 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias